Atrium Therapeutics, Inc. (NASDAQ: RNA) is a Healthcare company (Biotechnology) with a market capitalization of $140M. The Maz Rating grades it against the other companies in its sector.
Atrium Therapeutics, Inc.'s current Maz Rating and its five factor grades are for members: log in to see them.
At $6.48, Atrium Therapeutics, Inc. trades at 655.1x sales and 6.4x book value. Over the last twelve months it generated about $213388 of revenue and a net loss of $8M. It runs a gross margin of 80.4%, an operating margin of -3576.0% and a net margin of -3310.8%. It shows return on equity of -35.8%, return on invested capital of -34.8% and a free cash flow yield of -4.8%. On the balance sheet: a debt-to-equity ratio of 0.06 and a current ratio of 9.20. Over the past 52 weeks the share price ranged from $6.36 to $16.77, with a beta of 0.37.
Atrium Therapeutics, Inc. does not currently pay a dividend.
16 Wall Street analyst ratings cover the stock: 8 Buy and 8 Hold, for a Buy consensus. This is the sell side's view, separate from the Maz Rating.
Atrium Therapeutics, Inc. is a biopharmaceutical company dedicated to revolutionizing the treatment of cardiomyopathies by delivering innovative ribonucleic acid (RNA) therapeutics directly to the heart. Their development-stage portfolio currently includes ATR 1072, a siRNA-based therapy targeting the PRKAG2 gene for the treatment of PRKAG2 syndrome, and ATR 1086, another siRNA therapy aimed at the PLN gene to address PLN cardiomyopathy. The company is also actively developing a wider range of pipeline candidates designed to combat various genetic and cardiac diseases. Founded in 2025, Atrium Therapeutics is based in San Diego, California.
Figures are trailing twelve months unless stated. The Maz Rating and Maz Dividend Score rank a company against its own sector; they are not price targets or recommendations.
No. As of September 2026, Atrium Therapeutics, Inc. (RNA) is classified as NOT HALAL by Maz Vantage: it fails every published Shariah screening standard it could be measured against (AAOIFI, S&P Global, Dow Jones, MSCI and FTSE).
| Standard | Ratios (value / limit) | Result |
|---|---|---|
| AAOIFI | Debt / Mkt Cap (36m) 0.00% / 30% · (Cash+Inv) / Mkt Cap (36m) 140.7% / 30% · Interest income / Revenue 14.3% / 5% | Fail |
| S&P Global | Debt / Mkt Cap (36m) 0.00% / 33% · (Cash+ST Inv) / Mkt Cap (36m) 140.7% / 33% · Receivables / Mkt Cap (36m) 9.10% / 49% · Interest income / Revenue 14.3% / 5% | Fail |
| Dow Jones | Debt / Mkt Cap (24m) 0.00% / 33.33% · (Cash+ST Inv) / Mkt Cap (24m) 140.7% / 33.33% · Receivables / Mkt Cap (24m) 9.10% / 33.33% · Interest income / Revenue 14.3% / 5% | Fail |
| MSCI | Debt / Avg Assets (4Q) 0.39% / 33.33% · (Cash+ST Inv) / Avg Assets (4Q) 92.7% / 33.33% · Receivables / Avg Assets (4Q) 2.69% / 33.33% · Interest income / Revenue 14.3% / 5% | Fail |
| FTSE | Debt / Total Assets 0.00% / 33.33% · (Cash+ST Inv) / Total Assets 87.9% / 33.33% · (Cash+Recv) / Total Assets 93.6% / 33.33% · Interest income / Revenue 14.3% / 5% | Fail |
No. As of September 2026, Atrium Therapeutics, Inc. (RNA) is classified as NOT HALAL by Maz Vantage: it fails every published Shariah screening standard it could be measured against (AAOIFI, S&P Global, Dow Jones, MSCI and FTSE).
No. Atrium Therapeutics, Inc. is over the AAOIFI limit on (Cash+Inv) / Mkt Cap (36m) and Interest income / Revenue.
About 14.3% of each dividend: Atrium Therapeutics, Inc.'s interest income as a share of its revenue. Give that share to charity; the dividend purification calculator works it out per holding.
The screen is rerun on each quarterly report; the figures here are from the balance sheet dated September 30, 2026 (Q3 2026). A status can change from one quarter to the next as debt, cash and market value move.
See also the list of halal stocks, halal healthcare stocks, the halal stock screener, the dividend purification calculator and the zakat calculator.
A mechanical screen of published financial ratios and the company's line of business, not a religious ruling. It does not test every revenue stream; check with a scholar you trust.